Abstract
The increased number of cases of type 2 diabetes mellitus (both diagnosed and undiagnosed) parallels the current epidemic of obesity in the United States. Despite receiving treatment, many patients do not achieve established therapeutic goals. Type 2 diabetes mellitus is a progressive disease characterized by multiple abnormalities that extend beyond β-cell dysfunction and insulin resistance. Incretin-based agents, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become important options in the therapeutic paradigm for patients with type 2 diabetes mellitus. The author reviews physiologic mechanisms of the incretin system and discusses the practical application of GLP-1 receptor agonists and DPP-4 inhibitors in improving GLP-1 dynamics in patients with type 2 diabetes mellitus.
| Original language | American English |
|---|---|
| Journal | Journal of the American Osteopathic Association |
| Volume | 112 |
| State | Published - Jan 1 2012 |
Keywords
- blood glucose
- diabetes mellitus
- glucagon-like peptide 1
- humans
- hypoglycemic agents
- treatment outcome
- type 2
Disciplines
- Endocrine System Diseases
- Endocrinology, Diabetes, and Metabolism
- Medicine and Health Sciences